COMMERCIAL POTENTIAL FOR P26 IN VITRO AND IN VIVO

P26 体外和体内的商业潜力

• 批准号: 2868071
• 负责人: Mitchell C. Sanders
• 金额: $ 10万
• 依托单位: ECI BIOTECH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-04-01 至 1999-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2868071
• 关键词: Branchiopoda; bacterial DNA; crystallins; gene expression; liquid chromatography; molecular cloning; protein folding; protein purification; stress proteins; technology /technique development; thermophilic organism; transfection /expression vector

Expressive Constructs Inc. is a small service based biotechnology company that was founded in 1998 to address the growing need for innovative developments in protein expression and liquid chromatography applications. the focus of this SBIR project grant is to develop a novel system for bacteria that will dramatically improve the yield of soluble and active proteins, many of which may prove useful in health-related applications. The novel approach is to utilize robust and general purpose protein genes from shrimp. It will be determined whether proteins from shrimp can assist proper folding of recombinant proteins that are not normally soluble when expressed in E. coli. Since these proteins also stabilize aggregation-prone protein intermediates, and inhibit certain classes of proteases, the second goal of this SBIR grant is to examine the feasibility of using this class of proteins for liquid chromatography applications. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Expressitive Construction Inc.是一家以服务为基础的小型生物技术公司，成立于1998年，旨在满足蛋白质表达和高效液相色谱应用领域日益增长的创新开发需求。这项SBIR项目拨款的重点是为细菌开发一种新的系统，该系统将显著提高可溶性和活性蛋白质的产量，其中许多蛋白质可能被证明在与健康相关的应用中很有用。新的方法是利用来自虾的健壮和通用的蛋白质基因。将确定虾中的蛋白质是否可以帮助重组蛋白正确折叠，这些重组蛋白在大肠杆菌中表达时通常不能溶解。由于这些蛋白质还稳定易于聚集的蛋白质中间体，并抑制某些类型的蛋白酶，因此SBIR赠款的第二个目标是研究将这类蛋白质用于液相色谱应用的可行性。建议的商业应用：不可用